Acute Otitis Media (AOM) in Pediatrics: Diagnosis and Management

Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint

Clinical Pathway

Acute Otitis Media (AOM) is characterized by acute onset of symptoms (fever, ear pain) and signs of middle ear inflammation, such as a bulging tympanic membrane. The first-line antibiotic therapy for AOM is Amoxicillin, given at a high dose (80-90 mg/kg/day). Amoxicillin is effective against the most common bacterial pathogen, Streptococcus pneumoniae. If the patient has been treated with amoxicillin in the past 30 days, or has concurrent purulent conjunctivitis, Amoxicillin-clavulanate is preferred to cover beta-lactamase-producing organisms like H. influenzae.

Clinical Reasoning

The clinical presentation of fever, ear pain, and a bulging tympanic membrane strongly suggests Acute Otitis Media (AOM). The bulging TM is the hallmark sign differentiating AOM from otitis media with effusion. High-dose Amoxicillin is the standard first-line treatment as it adequately targets susceptible and intermediate-resistant strains of Streptococcus pneumoniae, the most common etiology. Alternatives like Azithromycin or Cefdinir are considered in patients with penicillin allergies, while Amoxicillin-clavulanate is reserved for specific cases where beta-lactamase producers are suspected.

Sample MCQ

A 6-year-old boy presents with a 2-day history of right ear pain and fever. Examination reveals a bulging, erythematous right tympanic membrane with absent light reflex. What is the most appropriate first-line treatment?

  • AAzithromycin
  • BAmoxicillin
  • CCefdinir
  • DObservation only

Correct Answer: Amoxicillin

The clinical presentation is classic for Acute Otitis Media (AOM). The first-line antibiotic treatment for AOM in children, in the absence of penicillin allergy or recent amoxicillin use, is high-dose Amoxicillin. It targets the most common bacterial causes, particularly Streptococcus pneumoniae.

Related Clinical Topics

AIDS

AIDS (Acquired Immunodeficiency Syndrome) is the final, most severe stage of HIV infection, characterized by a profoundly compromised immune system that makes individuals highly susceptible to opportunistic infections and certain cancers. It is diagnosed when the CD4+ T-cell count drops below 200 cells/mm³ or when specific AIDS-defining opportunistic illnesses develop. The cornerstone of AIDS treatment is highly active antiretroviral therapy (HAART), a combination of drugs that suppress HIV replication, preserve immune function, and prevent further progression. HAART significantly reduces viral load, increases CD4+ T-cell counts, and improves overall health. Treatment also includes prophylactic antibiotics to prevent opportunistic infections and specific therapies for any active infections or cancers. Symptoms of AIDS are primarily due to the opportunistic infections and cancers that take advantage of the severely weakened immune system. Common manifestations include persistent fever, chronic diarrhea, significant unintentional weight loss, night sweats, fatigue, swollen lymph nodes, and recurrent severe infections like Pneumocystis pneumonia, Kaposi's sarcoma, and toxoplasmosis. Neurological complications such as AIDS dementia complex can also occur.

Bradycardia

Bradycardia is a medical condition characterized by a slower than normal heart rate, typically defined as fewer than 60 beats per minute (bpm) in adults. While sometimes physiological and benign, it can also indicate underlying cardiovascular or systemic issues that impair the heart's ability to effectively pump blood. Treatment for bradycardia depends on its underlying cause, severity, and the presence of symptoms. Asymptomatic bradycardia, especially in athletes, often requires no intervention. Symptomatic bradycardia may necessitate discontinuing or adjusting causative medications, treating underlying conditions, or in severe cases, implanting a permanent pacemaker to regulate heart rhythm. Acute, unstable bradycardia may require intravenous atropine or temporary pacing. Clinical manifestations range from asymptomatic presentation to severe symptoms depending on the degree of bradycardia and the patient's cardiovascular reserve. Common symptoms include fatigue, dizziness, lightheadedness, syncope (fainting), shortness of breath, and chest pain. In critical cases, it can lead to confusion, hypotension, and signs of organ hypoperfusion.

Chronic Hepatitis C Virus infection

Chronic Hepatitis C Virus (HCV) infection is a persistent inflammatory condition of the liver caused by the hepatitis C virus, defined by the presence of detectable HCV RNA for at least six months. This long-term infection can progressively lead to significant liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma. Current treatment primarily involves direct-acting antiviral (DAA) medications, which are highly effective oral regimens targeting specific viral proteins to inhibit HCV replication. These therapies typically achieve a sustained virologic response (SVR) in over 95% of patients, effectively curing the infection. Treatment duration usually ranges from 8 to 12 weeks, depending on the specific regimen and patient factors. Chronic HCV infection is often asymptomatic for many years, leading to a silent progression of liver disease. When symptoms do appear, they are often non-specific, such as fatigue, malaise, nausea, and right upper quadrant discomfort. As the disease advances to cirrhosis, signs of liver decompensation may emerge, including jaundice, ascites, peripheral edema, spider angiomata, and hepatic encephalopathy.

SMLE Preparation Resources

Master the 2026 SMLE

Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.

Try the QBank & Scaled Mocks